IRIS - Res&Arch Institutional Research Information System - Research & Archive

SCHIAROLI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.429
AS - Asia 1.983
EU - Europa 1.610
SA - Sud America 403
AF - Africa 39
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.360
SG - Singapore 983
IT - Italia 425
IE - Irlanda 374
HK - Hong Kong 341
BR - Brasile 334
CN - Cina 313
RU - Federazione Russa 224
VN - Vietnam 135
DE - Germania 131
GB - Regno Unito 76
KR - Corea 73
FI - Finlandia 71
UA - Ucraina 60
SE - Svezia 51
CA - Canada 40
AT - Austria 39
EE - Estonia 36
FR - Francia 35
AR - Argentina 25
IN - India 22
TR - Turchia 20
NL - Olanda 19
PL - Polonia 17
JP - Giappone 16
MX - Messico 16
BD - Bangladesh 14
ID - Indonesia 14
ZA - Sudafrica 13
BE - Belgio 12
CH - Svizzera 10
IQ - Iraq 9
UZ - Uzbekistan 9
ES - Italia 8
VE - Venezuela 8
EC - Ecuador 7
PY - Paraguay 7
CL - Cile 6
CO - Colombia 6
EG - Egitto 6
AE - Emirati Arabi Uniti 5
JO - Giordania 5
LT - Lituania 5
PE - Perù 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
KE - Kenya 4
AZ - Azerbaigian 3
BO - Bolivia 3
CR - Costa Rica 3
IL - Israele 3
IR - Iran 3
PK - Pakistan 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
AU - Australia 2
GR - Grecia 2
HN - Honduras 2
MA - Marocco 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
HR - Croazia 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MG - Madagascar 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
QA - Qatar 1
SN - Senegal 1
SR - Suriname 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
WS - Samoa 1
ZW - Zimbabwe 1
Totale 6.470
Salva come PNG Salva come JPEG
Città #
Singapore 632
Dublin 374
Hong Kong 341
Chandler 318
Perugia 183
San Mateo 169
Boardman 125
Santa Clara 122
Altamura 116
Ashburn 108
Dearborn 94
Medford 83
Princeton 83
Lawrence 80
Moscow 76
Seoul 72
Beijing 65
Los Angeles 63
Munich 59
Ann Arbor 55
Wilmington 55
New York 54
Andover 51
Columbus 49
The Dalles 42
Dong Ket 39
Ho Chi Minh City 38
São Paulo 36
Falls Church 30
Piscataway 28
Des Moines 24
Helsinki 22
Nuremberg 22
Redmond 22
Hanoi 20
Hefei 20
Turku 18
Rio de Janeiro 17
Saint Petersburg 17
Tokyo 16
Vienna 16
Florence 14
San Paolo di Civitate 14
Amsterdam 13
Montreal 13
Norwalk 13
Brussels 12
Chicago 12
Frankfurt am Main 12
Jacksonville 12
Warsaw 12
Houston 11
Poplar 11
Rome 11
London 10
Dallas 9
Ottawa 9
Padova 9
San Francisco 9
Woodbridge 9
Ankara 8
Bastia umbra 8
Boston 8
Falkenstein 8
Toronto 8
Brasília 7
Brooklyn 7
Chennai 7
Johannesburg 7
Manchester 7
Mexico City 7
Orem 7
Redwood City 7
Tashkent 7
Atlanta 6
Belo Horizonte 6
Bologna 6
Curitiba 6
Espoo 6
Guangzhou 6
Izmir 6
Lappeenranta 6
Nanjing 6
Porto Alegre 6
Stockholm 6
Amman 5
Denver 5
Kunming 5
Nanning 5
Ningbo 5
Shanghai 5
Campinas 4
Charlotte 4
Da Nang 4
Den Haag 4
Haiphong 4
Jakarta 4
Jinan 4
Manaus 4
Milan 4
Totale 4.304
Salva come PNG Salva come JPEG
Nome #
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 112
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 112
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients 108
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 103
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected 98
Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2 94
Partial achievement of the 90-90-90 UNAIDS target in a cohort of HIV infected patients from Central Italy 93
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 91
Effects of antiretroviral therapy on lipid and immunovirological profile: Focus on proprotein convertase subtilisin/kexin 9 89
A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV patients on stable antiretroviral therapy 89
Biochemical markers of bone turnover and calcium dietary intake evaluation in HIV-infected patients 84
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 83
Role of nucleocapsid protein antigen detection for safe end of isolation of sars-cov-2 infected patients with long persistence of viral rna in respiratory samples 83
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 82
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 81
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa 79
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 79
Seroprevalence of anti-SARS-CoV2 antibodies in umbrian persons living with HIV 79
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 79
Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy. 78
Predictive risk factors for worse outcomes in COVID-19 patients with different clinical features at baseline 78
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 77
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 76
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 76
Reactivation of hepatitis B virus replication due to cytotoxic therapy:a five-year prospective study 76
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 75
The association between neutrophil to lymphocyte ratio and endothelial dysfunction in people living with HIV on stable antiretroviral therapy 75
Low brachial artery flow-mediated dilation predicts worse prognosis in hospitalized patients with covid-19 75
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 74
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 74
Early treatment with bamlanivimab alone does not prevent COVID-19 hospitalization and its post-acute sequelae. A real experience in Umbria, Italy 73
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 71
Bone-turnover markers in white HIV-infected patiens treated with or without TDF-containg regimens 70
Prevalence of smoking and nicotine dependence in HIV patients, the project STOPS HIV from Italy 70
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 70
Lingual tubercolosis: a rare disease in western countries 69
Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters 69
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 68
An explainable model of host genetic interactions linked to COVID-19 severity 67
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 67
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 66
The HIV Matrix Protein p17 promotes the Activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 66
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial 66
Percutaneous vertebroplasty improves pain control and quality of life in patients suffering from back pain: A single center experience 66
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 66
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients 66
A first update on mapping the human genetic architecture of COVID-19 64
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: A cross-sectional analysis 64
Genetic mechanisms of critical illness in COVID-19 64
Diagnosis of Nocardia paucivorans central nervous system infection by DNA sequencing from paraffin-embedded tissue 63
Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital. 63
Mapping the human genetic architecture of COVID-19 63
BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV 62
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 62
Meningitis with cranial polyneuritis and cavernous sinus thrombosis by Borrelia crocidurae: First autochthonous case in Europe 59
Protective role of a tmprss2 variant on severe covid-19 outcome in young males and elderly women 58
Whole-genome sequencing reveals host factors underlying critical COVID-19 57
Is the rate of virological failure to cART continuing to decline in recent calendar years? 57
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 57
Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) 56
Nelfinavir: An Old Ally in the COVID-19 Fight? 54
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? 54
Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir 54
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 53
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 53
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism 53
Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm 53
HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes 52
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 52
Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry 52
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 52
Management of Meningitis Caused by Multi Drug-Resistant Acinetobacter Baumannii: Clinical, Microbiological and Pharmacokinetic Results in a Patient Treated with Colistin Methanesulfonate 51
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 51
Gangrenous Chickenpox with Atypical Clinical and Histopathological Findings. 51
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level 51
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 50
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting 50
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 50
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients 49
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART 47
Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach 47
The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication 46
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 46
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 45
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report 45
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study 45
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 44
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 44
Transgender people living with HIV: characteristics and comparison to homosexual and heterosexual cisgender patients in two Italian teaching hospitals 44
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 44
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 44
Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy 43
Elevated serum uric acid levels are associated with endothelial dysfunction in HIV patients receiving highly-active antiretroviral therapy 43
Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry 43
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 42
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 42
Validation of a self-reported HIV symptoms list: The ISS-HIV symptoms scale 39
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 39
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 38
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 37
Totale 6.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.765
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.765
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021113 0 0 0 0 0 8 9 21 21 6 8 40
2021/2022663 29 120 5 12 27 17 14 179 30 47 94 89
2022/20231.260 88 269 17 109 92 106 9 39 469 0 36 26
2023/2024512 27 71 20 8 5 3 134 4 28 29 102 81
2024/20251.837 26 132 65 63 212 85 160 91 415 132 288 168
2025/20261.765 247 225 241 471 469 112 0 0 0 0 0 0
Totale 6.790